New imaging agent could sharpen cancer detection
NCT ID NCT07510321
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study is testing a new imaging agent called FL-261 in 12 people with advanced cancers like lung, colorectal, or head & neck cancer. The agent targets a protein called c-MET that is often found on cancer cells. Researchers want to see if FL-261 scans can safely and accurately show where the cancer is, compared to standard scans. If it works, it could lead to a more precise way to diagnose and stage these cancers without needing a biopsy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FL-261 (a radiolabeled imaging agent)
What this could lead to
If successful, this could provide a more accurate, non-invasive way to diagnose and stage cancers like lung, colorectal, and head & neck cancer, potentially guiding better treatment decisions.
What could go wrong
This is a very early, small study with only 12 participants. It is testing the imaging agent's safety and basic function, not its effectiveness yet. The results may not apply to all patients or cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Union Hospital
RECRUITINGWuhan, Hubei, 430022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••